Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) Files An 8-K Regulation FD Disclosure
Item 7.01 by reference to Exhibit 99.1, are being furnished, and
shall not be deemed filed, for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to liability under that section, nor shall they be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, except as shall be expressly set forth by
specific reference in such a filing.
Item 2.02
Results of Operations and Financial Condition
On December 22, 2016, Ohr Pharmaceutical, Inc., a Delaware
corporation, issued a press release announcing its results for
the fiscal year ended September 30, 2016. This press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated herein by reference.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits:
| 99.1 | Press release, dated December 22, 2016. | |
About Ohr Pharmaceutical, Inc. (NASDAQ:OHRP)
Ohr Pharmaceutical, Inc. is a pharmaceutical company. The Company is focusing on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company’s development pipeline consists of various programs and indications at various stages of development. The Company’s clinical program, OHR-102 eye drops, is a therapeutic product that provides a non-invasive therapy to improve vision outcomes without requiring multiple injections per office visit. The Company focuses on OHR-102 eye drops, which is given in combination with Lucentis injections, for the treatment of retinal diseases, including wet-age-related macular degeneration (AMD), retinal vein occlusion and proliferative diabetic retinopathy. The Company’s product pipeline also includes SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry-AMD and Non-Ophthalmology Assets. OHR-102 is a small molecule anti-angiogenic drug with an intracellular mechanism of action. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) Recent Trading Information
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) closed its last trading session down -0.10 at 1.65 with 174,968 shares trading hands.
